Mabwell Bioscience Partners with Aditum Bio to Launch Kalexo Bio for siRNA Cardiovascular Therapy Mabwell and Aditum Bio have founded Kalexo Bio to develop innovative siRNA therapies targeting cardiovascular disorders, promising new hope for patients.

Mabwell Bioscience Partners with Aditum Bio to Launch Kalexo Bio for siRNA Cardiovascular Therapy #China #Shanghai #Mabwell_Bioscience #Aditum_Bio #Kalexo_Bio